IONIS PHARMACEUTICALS INC's ticker is IONS and the CUSIP is 462222100. A total of 366 filers reported holding IONIS PHARMACEUTICALS INC in Q3 2020. The put-call ratio across all filers is 1.27 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $8,716,378 | +16.3% | 192,160 | +5.2% | 0.00% | +50.0% |
| Q2 2023 | $7,496,755 | -52.6% | 182,714 | -58.7% | 0.00% | -60.0% |
| Q1 2023 | $15,826,169 | +91312.1% | 442,885 | -3.4% | 0.01% | 0.0% |
| Q4 2022 | $17,313 | -99.9% | 458,444 | -18.3% | 0.01% | -50.0% |
| Q3 2022 | $24,810,000 | +14.6% | 560,928 | -4.1% | 0.01% | +25.0% |
| Q2 2022 | $21,658,000 | +65.5% | 585,048 | +65.5% | 0.01% | +100.0% |
| Q1 2022 | $13,089,000 | +11.2% | 353,481 | -8.6% | 0.00% | 0.0% |
| Q4 2021 | $11,767,000 | -1.4% | 386,691 | +8.7% | 0.00% | 0.0% |
| Q3 2021 | $11,935,000 | -27.1% | 355,839 | -13.3% | 0.00% | -20.0% |
| Q2 2021 | $16,362,000 | -20.4% | 410,217 | -10.3% | 0.01% | -28.6% |
| Q1 2021 | $20,563,000 | -19.0% | 457,281 | +1.8% | 0.01% | -22.2% |
| Q4 2020 | $25,396,000 | +18.6% | 449,104 | -0.5% | 0.01% | 0.0% |
| Q3 2020 | $21,420,000 | -13.3% | 451,318 | +7.7% | 0.01% | -18.2% |
| Q2 2020 | $24,710,000 | +49.9% | 419,071 | +20.2% | 0.01% | +22.2% |
| Q1 2020 | $16,482,000 | -10.1% | 348,572 | +14.8% | 0.01% | +28.6% |
| Q4 2019 | $18,336,000 | +9.0% | 303,529 | +8.1% | 0.01% | 0.0% |
| Q3 2019 | $16,820,000 | -4.3% | 280,785 | +2.7% | 0.01% | 0.0% |
| Q2 2019 | $17,570,000 | -28.9% | 273,351 | -10.3% | 0.01% | -30.0% |
| Q1 2019 | $24,720,000 | +56.2% | 304,577 | +4.0% | 0.01% | +42.9% |
| Q4 2018 | $15,827,000 | +14.2% | 292,868 | +9.0% | 0.01% | +40.0% |
| Q3 2018 | $13,860,000 | +40.0% | 268,699 | +13.1% | 0.01% | +25.0% |
| Q2 2018 | $9,902,000 | -5.5% | 237,618 | +0.0% | 0.00% | 0.0% |
| Q1 2018 | $10,473,000 | -7.4% | 237,581 | +5.7% | 0.00% | -20.0% |
| Q4 2017 | $11,309,000 | +9.3% | 224,811 | +10.2% | 0.01% | 0.0% |
| Q3 2017 | $10,347,000 | +3.3% | 204,022 | +3.7% | 0.01% | 0.0% |
| Q2 2017 | $10,014,000 | +46.3% | 196,812 | +15.6% | 0.01% | +66.7% |
| Q1 2017 | $6,847,000 | +47.1% | 170,316 | +75.0% | 0.00% | +50.0% |
| Q4 2016 | $4,656,000 | +503.1% | 97,341 | +361.7% | 0.00% | – |
| Q3 2016 | $772,000 | +180.7% | 21,082 | +78.4% | 0.00% | – |
| Q2 2016 | $275,000 | -93.9% | 11,814 | -89.4% | 0.00% | -100.0% |
| Q1 2016 | $4,510,000 | -25.1% | 111,407 | +14.6% | 0.00% | -25.0% |
| Q4 2015 | $6,020,000 | – | 97,216 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Tweedy, Browne Co LLC | 3,541,136 | $133,749 | 7.12% |
| Bellevue Group AG | 9,743,900 | $368,027,103 | 4.88% |
| M28 Capital Management LP | 126,300 | $4,770,351 | 4.55% |
| Sicart Associates LLC | 246,258 | $9,301,165 | 3.28% |
| Camber Capital Management LP | 1,925,000 | $72,707 | 2.49% |
| Privium Fund Management B.V. | 148,807 | $5,557,941 | 2.11% |
| Deep Track Capital, LP | 1,205,773 | $45,542,046 | 1.91% |
| BVF INC/IL | 1,121,809 | $42,370,726 | 1.79% |
| Orbimed Advisors | 1,993,600 | $75,298,272 | 1.44% |
| Parkman Healthcare Partners LLC | 141,115 | $5,329,914 | 1.42% |